CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in ...

Idera Pharmaceuticals’ TLR9 agonist has failed to improve on Yervoy in a phase 3 melanoma trial. The miss on the objective response rate endpoint sent shares in Idera down 55%, but the biotech is yet ...

Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis "This Phase 2 trial of IMO-8400 will enable us to evaluate over a 12-week ...

Idera's strugging stock was partially redeemed by good Phase II trial results in psoriasis. The moderate efficacy left investors unenthused, but Idera is touting its candidate as more than just ...

Idera Pharma and BioCryst Pharmaceuticals to Merge to Form a New Enterprise On January 22, 2018, BioCryst Pharmaceuticals and Idera Pharma signed a definitive merger agreement to form a new enterprise ...

Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis PASI Score Improvements Correlated with Downregulation ...

Idera Pharmaceuticals Announces Top-line Results from a Phase 2 Clinical Trial of IMO-2055 in Treatment of Patients with Advanced Head and Neck Cancer CAMBRIDGE, Mass., May 03, 2012 (BUSINESS WIRE) ...

Idera Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Trial of IMO-3100 in Patients with Psoriasis First Human Trial in Lupus Program Anticipated to Begin in 2012 CAMBRIDGE, Mass ...

Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals (NAS: IDRA) ...